✦ LIBER ✦

Therapy choices among older patients with lung carcinoma : An evaluation of two trials of the cancer and leukemia group B

✍ Scribed by Caio Max S. Rocha Lima; James E. Herndon II; Michael Kosty; Gerald Clamon; Mark R. Green

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 110 KB
Volume: 94
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survey of oncologists' perceptions of ba

Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials

✍ Alice B. Kornblith; Margaret Kemeny; Bercedis L. Peterson; Judith Wheeler; Jeffr 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

Quality of life among patients with Stag

Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy : Results from Cancer and Leukemia Group B 9066

✍ Jeffrey Peppercorn; James Herndon II; Alice B. Kornblith; William Peters; Tim Ah 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 2 views

## Abstract ## BACKGROUND The objective of this study was to compare the quality of life (QOL) after treatment among patients who had breast carcinoma with multiple positive lymph nodes. The patients were randomized to receive either high‐dose chemotherapy with autologous stem cell support (HDC) o